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PLANNING STUDIES ACCOUNTING FOR COMPETING RISKS
A. LATOUCHE AND R. PORCHER
Abstract. Recently, with the growth of statistical developments for competing risks anal-
ysis, some methods have been proposed to compute sample size and plan a study in such a
framework. These methods differ from a modelling approach: some are based on the Cox
regression model for the cause-specific hazard accounting or not for accrual and follow–up
period while another deals with the Fine and Gray regression model for the subdistribution
hazard of a competing risk. Nonetheless, these formulas rely on similar key parameters,
namely the difference one wishes to detect and the proportion of patients who will actually
experience the event of interest. Choices for these parameters have a drastic effect on the
sample size or equivalently the power. In this work, we compare these approaches and give
practical advices for planning studies in a competing risks framework.
1. Introduction
Competing risks analysis is now a standard approach in the analysis of clinical trials, partic-
ularly in the cardiovascular and the oncology field. Regression modelling and test for equality
of cumulative incidence tend to be used routinely and are now also available in standard sta-
tistical softwares. It appears that the advance in analyses accounting for competing risks do
not translate in the crucial phase of planning the trial. Some recent works proposed sample
size formula that rely on two proportional hazards models, namely the Cox model for the
cause–specific hazard function [1, 2] and the Fine and Gray model for the hazard function
associated to the cumulative incidence function [3]. These formulas, based on Schoenfeld’s
formula for the Cox model [4], rely on similar key parameters, namely the difference one wishes
to detect and the proportion of patients who will actually experience the event of interest. Of
note, the previous works pointed out that planning a study ignoring competing risks may lead
to an underpowered study. Thus from a pratical point of view, the practionner has different
options to plan a study accounting for competing risks.
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In this article we compare these approach and supplement the sample size formula for the
Fine and Gray model with the determination of the proportion of event of interest which was
lacking. A modified version of this sample size based on Renyi–type test is also proposed.
2. Sample size calculation
Let us consider a clinical trial where n patients will be randomly assigned to a control group
C or an experimental treatment group E, in respective proportions pC and pE . Suppose that
the patients are exposed to K disctinct and exclusive failure causes, defining a competing
risks setting. In such a case, data typically consist in both a failure time T ≥ 0 and a
failure cause ǫ ∈ {1, . . . ,K}. Among these K failure causes, some may represent transition
to transient (non-fatal) states, but we ignore future transitions and focus on time to the first
failure (event). We also consider that the main endpoint of the trial is the occurrence of one
of these K failure causes. In the sequel we will consider that 2 competing events act on the
population without any loss of generality. In addition, we assume the time to event data are
subject to administrative only i.e. there are no losses to follow–up during the trial. Patient
entry are staggered over an accrual period and all patients are followed until the end of the
trial. Under this condition, censoring times are independent of the failure times.
Two main strategies for analysis of the trial can be identified. Most common analyses focus
on comparing the cause-specific hazard under the control and the experimental treatment,
where the hazard of failure from cause 1 is defined as: λ1.(t) = dF1.(t)/S(t), where the
subscript ”·” denotes treatment arm (with C for control arm and E for experimental arm).
In previous expression, F1. is the cumulative incidence function of failure from the cause
of interest, i.e. F1.(t) = Pr(T ≤ t, ǫ = 1) and S.(t) = 1 − (F1.(t) + F2.(t)) is the event
free survival function. In such a case, comparisons are often performed against proportional
hazards alternatives, using a Cox model [5]. The other strategy consists in comparing the
corresponding event probabilities F1.(t), either directly with the Gray’s test [6] or using a
Cox-like model for the associated hazard [7]: α1.(t) = dF1.(t)/(1−F1.(t)). Detailed discussion
of the differences between both approaches can be found in [8].
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Assuming proportional hazards leads to following models:
λ1E(t) = λ1C(t)θ
and
α1E(t) = α1C(t)γ,
where θ and γ are the hazard ratio and the subdistribution hazard ratio, respectively. Each
is the measure of treatment effect under the considered approach. The hypotheses tested are
:
H0 : log θ = 0 vs H1 : log θ 6= 0
or
H0 : log γ = 0 vs H1 : log γ 6= 0,
according to the modelisation choice for quantifying treatment benefit.
In this setting, sample size formulas have been developed for both the Cox model [1, 2]
and the Fine and Gray model [3]. In each case, a required number of events e is computed
according to the type I and II error rates (α and β, respectively) and the assumed hazard ratio
under the alternative hypothesis. Indeed, both formulas are akin to the ”classical” formula
obtained for the Cox model (in a survival analysis setting) [4], and differ by the hazard ratio
considered. This leads to
e =
(
zα/2 + zβ
)2
(log θ)2 × pC × pE
for a cause–specific analysis and
e =
(
zα/2 + zβ
)2
(log γ)2 × pC × pE
for a subdistribution analysis, where zα denotes the (1− α)-quantile of the standard normal
distribution.
To plan the trial, one has to compute the total number of subjects n to be recruited to
obtain the required number of events e, as n = e/Ψ where Ψ is the probability of observing
the event of interest during the trial. The probability Ψ. in each treatment arm depends on
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F1., the duration of the accrual period τ1, the total duration of the trial τ2 and the distribution
of random entry times with density φ through:
(1) Ψ. =
∫ τ1
0
F1.(τ2 − s)φ(s)ds.
Ψ. is computed for both groups, and subsequently combined as:
Ψ = pCΨC + pEΨE.
Several works have been devoted to derivation of Ψ for survival studies under different
acrual patterns [9, 10]. For a cause–specific analysis, assuming uniform entry time and time-
homogeneous Markov model for each transition, the expected proportion of events expresses
as [2]:
(2) Ψ. =
λ1.
λ.
×
[
1−
exp(−λ.(τ2 − τ1)− exp(−λ.τ2)
λ.τ1
]
,
where λ1., . . . , λK. represent the K constant hazard rates, and λ. =
∑K
k=1 λk..
When using a subdistribution-based analysis [3], one also has to determine a value for Ψ.
Unfortunately, as both a Cox model and a Fine and Gray model cannot hold simultaneously,
except in the degenerate case where no other failure cause than the cause of interest occurs,
the expression (2) for Ψ should not be used for both treatment arms if proportional cause-
specific hazards are not assumed. However, it is still possible to assume a parametric form for
F1C (for instance that given above), and use the straightforward relation between cumulative
incidences in both groups, i.e.
F1E(t) = 1− [1− F1C(t)]
γ .
Even under simple parametric models, evaluating equation (1) with such an expression of
F1E(t) is not trivial, but Simpson’s rule provides the following approximation
(3) ΨE =
1
6
[
F1E(τ2) + 4F1E
(
τ2 −
τ1
2
)
+ F1E(τ2 − τ1)
]
.
To illustrate the implication in terms of number of event to be observed e, we use the
example taken from Schulgen et al. as a working example [2] . The 4D trial is a randomized,
double–bind, placebo–controlled trial to evaluate the efficacy of antihyperlipidemic treatment,
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in reducing cardiovascular mortality and frequency of non–fatal myocardial infarction. In this
trial more than one primary event of interest and competing risks are present. Notably, it can
be summarized by a multi–state model with initial state ”alive” and the outcome states for
the primary endpoint ”non–fatal myocardial infarction” (state 1) and ”death of cardiovascular
cause” (state 2) and the additional outcome state death of other causes (state 3).
In the sequel, we considered the composite endpoint combining states 1 and 2 (non–fatal
myocardial infarction and death of cardiovascular cause), death of other causes being the
competing event. Reparameterizing the model accordingly leads to λ1C = 0.26, λ1E = 0.19
and λ2C = λ2E = 0.14. Thus θ = λ1E/λ1C= 0.73 and γ = log(1− F1E(4))/ log(1− F1C(4))=
0.75. With α = 5% and β = 10%, the required number of events is 424 and 504, respectively.
Under uniform accrual assumption with an accrual duration τ1 = 1.5 years and a total
duration τ2 = 4 years, the proportion Ψ obtained for a cause–specific model are ΨC = 0.470
and ΨE = 0.377. For a subdistribution analysis, very similar results are obtained with
ΨC = 0.470 and ΨE = 0.379. This would lead to a trial of 1002 patients for a cause–specific
analysis and 1190 patients for a subdistribution analysis.
In this example, both approaches lead to very similar anticipated proportions of events.
Still using the hazard rates of the 4D trial, the differences between both proportions were
very limited for trial durations varying from 3 to 9 years and accrual durations varying from
6 months to 3.5 years. In all these cases, the relative difference between the anticipated
proportions of events was always less than 2%. For shorter trials, the anticipated proportion
of events was found to be slightly larger when using equation (3), while the converse was
found for longer durations. Reducing the accrual period led to closer values for Ψ obtained
with both methods, whereas longer accrual periods yielded larger differences. In the example,
both hazard ratios θ and γ were quite similar. Nonetheless, as the required number of events
is inversely proportional to the logarithm of the hazard ratio, the influence of this apparently
small difference was quite important in terms of sample size. Actually, as the relative difference
between both hazard ratios was less than 3%, the relative difference between the numbers of
events is only slightly inferior to 20%.
[Figure 1 about here.]
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This is also illustrated on Figure (1), that displays the influence of a relative variation in
parameter on the relative variation in sample size. It appears that differences in the proportion
of events of interest, which may arise from the choice of one model vs. the other or from a
misspecification of the true accrual or survival pattern, have little influence on the sample size,
or equivalently the power. On the contrary, even a reasonable error on the targeted hazard
ratio may lead to dramatic modifications of the sample size. This stresses the importance to
select the model that will be used with care. In particular, if it is the planned analysis to
analyze the trial by comparison of the subdistribution functions, the sample size should not
be computed on the basis of a cause-specific analysis, and conversely.
3. Sample size formulas for Renyi–type tests
In previous section, both sample size formulas depend on the model chosen for inference,
irrespective to the verification of this model assumptions. However, it is well known that the
power of both tests is sensible to proportional hazard. As trial planning precedes the check of
model assumptions it may be useful to anticipate possible departures from the proportional
hazards by using a test statistic less sensitive to this proportionality assumption. This is
precisely the case of Renyi–type tests aka supremum log–rank tests in the classical survival
framework [11]. Moreover, recent work on sample size has shown that this test is nearly as
efficient as the logrank test when hazards are proportional, and can accomodate with broader
range of alternatives where the log–rank has no power to distinguish between groups [12].
Additionally, Renyi–type test statistics have already been extended to the comparison of
subdistribution functions in the unpublished Ph.D. thesis of Bajorunaite [13]. We thus derive
the sample size formula for this test.
We briefly present the sample size for the supremum log–rank statistic. Standardized
weighted logrank are based on the counting process integral
Vn(t) = n
−1/2
∫ t
0
Wˆn(s)
RC(u)RE(u)
RC(u) +RE(u)
{
dNC(u)
RC(u)
−
dNE(u)
RE(u)
}
,
with N. and R. are the counting and at–risk processes in treatment arm ”·” and where Wˆn is
an estimated weight function. Let σ2n(t) be the variance of Vn(t) and τ be the total duration
PLANNING STUDIES ACCOUNTING FOR COMPETING RISKS 7
of the trial, then Tn(τ) is the standardized weighted logrank where Tn(t) = Vn(t)/σn(t). The
corresponding supremum version is supt∈[0,τ ] |Tn(t)|.
The sample size formula is based on the limiting distribution of supt∈[0,τ ] |Tn(t)| with pro-
portional hazards contiguous alternative. Statistical derivations can be found in [12] and the
methodology to compute sample size can be summarize as follow: a sample size n˜ is first
computed via Schoenfeld’s formula; then an adujstment for the supremum version is com-
puted as n = R × n˜. This adjustment factor R is surprisingly only a function of α and β
anf thus does not depend neither on the weight functions nor the true underlying model for
the hazard function. An R function is available to compute this factor and can be found at
http://www.bios.unc.edu/~kosorok/renyi.html.
Similarly, Gray’s test is based on the scores of the form:
Z. =
∫ τ
0
W.(u)
{
dΓˆ1.(u)− dΓˆ
0
1(u)
}
,
withW. is a positive weight function, Γˆ1.(t) is the estimated cumulative subdistribution hazard
for the cause of interest in treatment arm ”·” and Γˆ01(t) is the cumulative subdistribution
hazard estimates pooling treatment arms C and E.
In the two-sample problem and taking weight equal to 1, Renyi-type analogous for Gray’s
test can be based on:
(4) Z1(t) =
∫ t
0
RC(u)RE(u)
RC(u) +RE(u)
{
dN1C(u)
RC(u)
−
dN1E(u)
RE(u)
}
,
where N1.(t) is the number of events of interest in the treatment arm ”·” by t and R.(t) =
I(τ ≥ t)Y.(t)[1 − Fˆ1.(t−)]/Sˆ.(t−).
The Gray’s test variance is complicated to evaluate but Klein and Bajorunaite [14] have
proposed a simplified estimator for the variance of Z1(t), that reduces to:
(5)
σˆ2(t) =
∫ t
0
RC(u)RE(u)
RC(u) +RE(u)
×
RE(u)
(
1− Fˆ1E(u−)
)
+RC(u)
(
1− Fˆ1C(u−)
)
RC(u)
(
1− Fˆ1E(u−)
)
+RE(u)
(
1− Fˆ1C(u−)
)×
{
dN1C(u) + dN1E(u)
RC(u) +RE(u)
}
.
In this two-sample case, Gray’s test correspond to the test statistic TG = Z1(τ)/σˆ(τ), whereas
the corresponding Renyi-type supremum version is TR = supt∈(0,τ ] |Z1(t)/σˆ(τ)| [13].
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The work of Latouche et al. [3] showed that Schoenfeld’s formula can be transposed to
the Fine and Gray model with a similar expression, where the subdistribution hazard ratio γ
stands for the hazard ratio θ. Thus when analysing data based on subdistribution hazard the
first step is to compute the Schoenfled’s like formula from Latouche et al. [3] then to correct
it with the factor R .
4. A Simulation Study
A limited simulation study was conducted to illustrate the performance of the proposed
test statistic TR, comparatively to the others. Parameters of the simulations were determined
to grossly mimic the 4D trial with different situations. Two scenarios were considered: cause-
specific simulations and subdistribution simulations. In the first case, independent latent
failure times for each failure cause (1 and 2) were generated for each treatment arm. Then,
the time to first event and the corresponding failure cause were taken for (T, ε). As latent
failure times were independent, the cause-specific hazards were equal to the marginal hazards
of each failure cause. In the second case, time to failure from each cause were directly generated
from improper Gompertz models, such as the one recently proposed by Jeong and Fine [15]
for direct modelling of subdistribution functions . Briefly the subdistribution of failure from
cause k in each arm is expressed as a function of two parameters as:
Fk.(t) = 1− exp [βk. {1− exp(νk.t)} /νk.] ,
with νk. < 0 and |βk.| <∞. Parameters were chosen to ensure that the limits of the subditri-
butions of both failure causes summed up to unity. With such a model, the subdistribution
hazard for failure from cause 1 can be expressed as α1.(t) = β1. exp(ν1.t). In particular, this
enables to generate data arizing from the model of Fine and Gray as long as ν1C = ν1E . For
each scenario (cause–specific or subdistribtion),time to event were generated for the following
hypothesis:
(a): under H0
(b): under a proportional hazards alternative
(c): under a nonproportional hazards alternative
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In cause-specific scenarios (a) and (b) independent exponential failure time were considered
with respective hazards λ1C = 0.26 and λ2C = 0.14 in the control group while λ1E = 0.19
and λ2E = 0.14 in the experimental group. For the nonproportional alternative (c) λ1E was
piecewise constant, keeping λ2C = 0.14 as shown on Figure (2).
[Figure 2 about here.]
In all cases we compared the performance of the logrank test, supremum logrank, Gray test
and our proposed Renyi–type test. The sample size and the parameter were taken from our
working example.
Under the null hypotesis, the values of νk. and βk. were taken to reach a prevalence for the
event of interest P (ε = 1) = 0.65, with ν1. = ν2. = −0.3 and βk. = νk. log(1− 0.65) (=0.315).
The different settings for the alternatives hypothesis are displayed on Figure (2). For the
simulation study we considered the two sample sizes respectively based on a log–rank that is
1002 patients and 1190 patients for a subdistribution analysis .
To evaluate the sensitivity of the test statistics namely log–rank, Supremum log–rank, Gray
, and Renyi type test TR, 10,000 data sets where generated in each case and the observed
power and size were computed. The table 1 summarizes the simulation study.
[Table 1 about here.]
Under proportional cause–specific hazards (i.e. exponential model) and a sample size of 1002
patients, the log-rank expectidly performed better than the other tests. The proposed Renyi
test was the farthest from the nominal 90% power with a 85.1% observed power. If we consider
nonproportional hazards, the observed power diminished for all tests but the supremum log–
rank test achieves the greater observed power (79.5%). This exhibits one advantages over
standard log-rank. The proposed test performed better than Gray test with a 76.9% observed
power. Increasing the sample size to 1190, the proposed test performed well with an observed
power of 91%. The other test statistics led to over powered trials. Theses two settings clearly
favored the log–rank test and the supremum log-rank test.
In the setting of proportional subdistribution hazards (i.e. Gompertz model) with a trial
of 1002 patients, both Gray and Renyi tests achieved an observer power over 80% while the
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observed power of ohter tests collapsed. Indeed, the Gray test is expected to have an optimal
power when subdistibution hazards are proportional. When subdistributions were nonpro-
portional, none of the tests statistics appeared to be clearly favored. Both Gray and Renyi
tests observed power decreased to 73.9% and 75.5% respectively. Log–rank and supremum
log–rank observed power were 66.1% and 68.2%. Gray’s test was found to be more sensitive to
nonproportionality that the Renyi type test. Increasing sample size to 1190, with proportional
subdistribution hazards, only Gray’s and Renyi tests observed powers were close to 90% , the
log-rank and supremum tests observed power being 15% under the targeted power. Such a
scenario favored subdistribution-based inference.
The Renyi type test is designed to accomodate departure form the proportional cause–
specific hypothesis. This is particularly the case for nonproportional subdistribution hazards
(indeed proportional cause specific hazards implies nonproportional subdistributions hazards)
where our proposed test observed power was the highest with 82.6%. The proposed test
statistics TR can accomodate either proportional hazards or nonproportional hazards with
better observed power when sample size formula accounting for competing risks (meaning
more patients).
Moreover, the observed size was close to the 5% targeted size in all settings for all test
statistics.
5. Discussion
When analysing data from a clinical trial accounting for the occurence of competing events,
some complementary analysis can be conducted. As illustrated in Figure 1, imprecisions in
parameter determination can lead to recruit much more patients than necessary or, on the
contrary, to a dramatic decrease of the power of the trial. Parameter determination is thus
a key issue when planning a trial, especially in survival trials with competing risks, where
these parameters will heavily depend on assumptions on the distributions of failure time that
are are almost unverifiable. The choice of the sample size formula is thus motivated by the
corresponding quantity of interest. The small simulation study we conducted covered a com-
bination of sample size and proportionality assumptions. It should be noted that in practice
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only the method for computing sample size is part of the choice, whereas model assumptions
can only be verified retrospectively. Proportionality assumptions are constraints toward test
statitics employed for inference. Thus, we recommend the use of the proposed Renyi type
test when planning studies accounting for competing risks because it can accomodate with
broader range of alternatives such as nonproportional hazards.
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Figure 1. Influence of misspecification of the hazard ratio or the proportion
of events of interest (Ψ) on the number of subjects
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Figure 2. Simulated hazard (left) (cause–specific (a) subdistribution (c)) be-
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Table 1. Size and Power Comparison, Relative to Modelisation and Test
Statistics Considering Proportional (PH) or Non-Proportional Hazards (NPH)
N = 1002 N = 1190
Test Size Power (PH) Power (NPH) Size Power (PH) Power (NPH)
Exponential model
Log-rank 0.053 0.908 0.796 0.051 0.942 0.847
Supremum log-rank 0.049 0.890 0.808 0.048 0.928 0.861
Gray 0.053 0.880 0.755 0.050 0.923 0.813
Adapted Renyi 0.050 0.863 0.783 0.046 0.910 0.835
Gompertz model
Log-rank 0.050 0.695 0.674 0.050 0.765 0.742
Supremum log-rank 0.046 0.686 0.697 0.049 0.749 0.763
Gray 0.050 0.860 0.743 0.051 0.912 0.812
Adapted Renyi 0.047 0.836 0.767 0.049 0.888 0.826
